TMOD2 Antibody

What are the key characteristics of TMOD2 antibodies available for research?

TMOD2 antibodies are available in both polyclonal and monoclonal formats, with varying specificities and applications. Polyclonal antibodies, such as the rabbit polyclonal antibody from Proteintech (15262-1-AP), have been validated for Western blot (1:500-1:2400 dilution), immunohistochemistry (1:20-1:200 dilution), and ELISA applications . These antibodies show reactivity with human, mouse, and rat samples. Monoclonal antibodies, like the mouse monoclonal antibody (68039-1-IG), recognize human, pig, rabbit, and chicken TMOD2 antigens and have been validated for similar applications .

The molecular weight of TMOD2 is approximately 39-40 kDa, which is consistent across antibodies from different manufacturers. When selecting an antibody, consider the specific application (WB, IHC, IF) and the species being studied.

How can I validate the specificity of a TMOD2 antibody?

Validating antibody specificity is crucial for accurate experimental interpretation. Multiple complementary approaches should be employed:

• Knockout/knockdown validation: The gold standard for antibody validation is testing in tissues from TMOD2 knockout mice or in cells with TMOD2 knockdown. Previous studies have verified custom-made TMOD2 antibodies using tissues from TMOD2 knockout mice .

• Cross-reactivity testing: Test the antibody against purified TMOD1-4 proteins to ensure isoform specificity, as demonstrated in previous validation studies .

• Multiple antibody comparison: Compare expression profiles using different antibodies. For example, a commercial TMOD2 antibody (Commercial AB/αTmod2-COM) was shown to generate a nearly identical immunoblot profile as a custom-made TMOD2 antibody (Custom AB/αTmod2-C.M.) .

• shRNA validation: Knockdown TMOD2 using shRNA and confirm signal reduction by immunoblotting or immunofluorescence. Studies have achieved approximately 50% knockdown efficiency in both CAD neuroblastoma cells and hippocampal neurons .

What are the optimal protocols for TMOD2 immunostaining in neuronal cultures?

For successful immunostaining of TMOD2 in neuronal cultures, consider the following methodological approach based on research protocols:

• Fixation: Fix cultured neurons (typically DIV15-21 for mature neurons) with 4% paraformaldehyde in PBS for 15 minutes at room temperature.

• Permeabilization: Permeabilize with 0.1% Triton X-100 in PBS for 5 minutes.

• Blocking: Block with 3-5% BSA or normal serum in PBS for 1 hour at room temperature.

• Primary antibody: Incubate with TMOD2 antibody at appropriate dilution (typically 1:100-1:500 for immunofluorescence) overnight at 4°C. Consider co-staining with neuronal markers like MAP2 for dendrites and Homer 1 for post-synaptic densities to aid in subcellular localization .

• Secondary antibody: Incubate with fluorophore-conjugated secondary antibody for 1-2 hours at room temperature.

• Imaging: TMOD2 is abundantly expressed in the somatodendritic compartment of neurons, as evidenced by its colocalization with MAP2, but it's also present in axons .

For antigen retrieval in tissue sections, research indicates using TE buffer pH 9.0 or alternatively, citrate buffer pH 6.0 .

How should I design experiments to study TMOD2's role in dendritic spine development?

When investigating TMOD2's role in dendritic spine development, consider these methodological approaches:

• Overexpression studies: Transfect neurons with fluorescently-tagged TMOD2 constructs (e.g., ClFP-WT TMOD2) to study its effects on spine reorganization. Previous studies transfected hippocampal neurons on DIV15 (when spines have already formed) and analyzed changes within 24 hours .

• Mutant TMOD2 constructs: Utilize mutated TMOD2 constructs that specifically disrupt:

  • Tropomyosin-binding ability (L29E/L134D mutations, known as TMOD2ED)

  • Actin-binding site 1 (L73D mutation, known as TMOD2A1)

  • Actin-binding site 2 (truncation removing residues from C-terminus, known as TMOD2A2)

• Spine analysis parameters: Quantify:

  • Spine numbers by morphological type (thin, mushroom, stubby)

  • Spine length

  • Branched spines (with more than one post-synaptic density cluster)

  • Excitatory shaft synapses

  • Filopodia and spinules

• Live imaging: Implement live imaging to monitor spine dynamics and motility in response to TMOD2 manipulation .

How can I differentiate between tropomyosin-dependent and independent functions of TMOD2?

To distinguish between tropomyosin-dependent and independent functions of TMOD2, implement the following methodological approach:

• Generate mutant constructs: Create expression constructs for wild-type TMOD2 and TMOD2ED (with L29E/L134D mutations) that specifically disrupt tropomyosin binding without affecting actin binding .

• Verify binding disruption: Confirm the disruption of tropomyosin binding using native gel electrophoresis. When mixed with γTM1bzip (a chimeric peptide containing the TMOD-binding site of TM5NM1 and TM5NM2), wild-type TMOD2 shows a band shift, while TMOD2ED does not .

• Confirm preserved actin binding: Verify that the mutations do not affect actin binding using actin nucleation assays. TMOD2ED should maintain similar nucleation ability to wild-type TMOD2 .

• Compare phenotypes: Express these constructs in neurons and compare their effects on:

  • Dendritic spine morphology and density

  • Excitatory shaft synapse formation

  • Filopodia and spinule numbers

  • Spine motility and dynamics

Functions affected by TMOD2ED but not by wild-type TMOD2 are likely tropomyosin-dependent. For example, overexpression of TMOD2ED significantly increased the number of excitatory shaft synapses compared to both wild-type TMOD2 and control, suggesting a tropomyosin-dependent regulation of shaft synapse formation .

What approaches can I use to study the interaction between TMOD2 and actin in dendritic spines?

To investigate TMOD2-actin interactions in dendritic spines, consider these methodological approaches:

• Structural analysis: Use molecular dynamics simulations (MDS) to analyze the structural interactions between TMOD2's LRR (leucine-rich repeat) domain and actin. Research has utilized the structure of TMOD1's LRR domain bound to actin (PDB 4PKI) as a template for modeling TMOD2-actin interactions .

• Quantify surface interactions: Analyze the solvent-accessible surface (SAS) and solvent-excluded surface (SES) in the binding interface. Research has shown that TMOD2 has an SAS of 230.7 Ų and SES of 183.8 Ų, with truncation causing an SAS reduction of 8.4 Ų (-4.5%) and SES increase of 3.3 Ų (+1.4%) .

• Mutational analysis: Create TMOD2 mutants with disruptions in specific actin-binding residues:

  • TMOD2A1 (L73D mutation): Disrupts the first actin-binding site

  • TMOD2A2 (truncation removing C-terminal residues): Disrupts the second actin-binding site

• Functional assays: Compare the effects of these mutations on:

  • Actin nucleation ability (using pyrene actin polymerization assays)

  • Pointed-end capping ability

  • Dendritic spine morphology and dynamics

Research has demonstrated that TMOD2 requires both actin-binding sites for nucleation, but maintains significant capping ability as long as either actin-binding site is functional .

What controls should I include when analyzing TMOD2 expression during neuronal development?

When analyzing TMOD2 expression during neuronal development, include these essential controls:

• Loading controls: Normalize TMOD2 levels to stable reference proteins such as tubulin. Research studies have normalized values to a tubulin loading control and then to a reference time point (e.g., "Adult" or "DIV21") .

• Developmental timeline: Establish a complete developmental timeline. Studies show that TMOD2 expression increases during embryonic stage 18 and remains relatively steady through adulthood in rat hippocampal neurons .

• Multiple detection methods: Validate findings using both Western blotting and immunofluorescence. This approach provides both quantitative expression data and information about subcellular localization .

• Isoform specificity: Test for potential compensatory changes in other tropomodulin isoforms, particularly TMOD1, which is also expressed in neurons. Research indicates that TMOD2 levels remain fairly constant in N2a neuroblastoma and PC12 cells throughout development .

• Subcellular markers: Include markers for different neuronal compartments (MAP2 for dendrites, Homer 1 for post-synaptic densities) to analyze compartment-specific expression changes .

How can I resolve contradictory results when studying TMOD2 function in different neuronal models?

When facing contradictory results across different neuronal models, consider these methodological approaches:

• Model-specific differences: Recognize that TMOD2 functions may differ between:

  • Cell lines (N2a, PC12, CAD cells) vs. primary neurons

  • Different primary neuron types (hippocampal vs. cortical)

  • Different developmental stages (DIV7-12 vs. DIV15-21)

• Temporal considerations: Distinguish between developmental effects and acute effects. Studies examining TMOD2 overexpression during developmental stages (DIV7-12) found different effects than those examining acute effects on spine reorganization (within 24 hours in mature DIV15 neurons) .

• Experimental approach: Consider how different manipulation techniques may yield different results:

  • Knockout vs. knockdown (complete absence vs. partial reduction)

  • Acute vs. chronic manipulation

  • Global vs. sparse manipulation

• Isoform compensation: Test whether contradictory results might be explained by compensatory changes in other tropomodulin isoforms. While some studies found no compensatory changes in TMOD1 when TMOD2 was knocked down in culture , other studies in knockout animals have observed compensation .

• Interaction with binding partners: Consider that TMOD2 function depends on interactions with tropomyosin and actin, which may vary across model systems. The specific tropomyosin isoforms expressed in different neuronal populations could influence TMOD2 function .

By systematically addressing these variables, researchers can better understand the biological basis of seemingly contradictory results and develop a more nuanced understanding of TMOD2 function in neuronal development and plasticity.

What are emerging techniques for studying TMOD2 dynamics in live neurons?

Emerging techniques for studying TMOD2 dynamics in live neurons include:

• Fluorescent fusion proteins: ClFP-tagged TMOD2 constructs have been successfully used for live imaging of spine dynamics and motility . Future research could utilize newer fluorescent proteins with improved brightness and photostability.

• Super-resolution microscopy: Techniques such as STED, PALM, or STORM could reveal TMOD2 localization at nanoscale resolution within dendritic spines, providing insights into its precise spatial relationship with actin filaments.

• Optogenetic manipulation: Light-inducible dimerization or activation systems could allow for acute, spatially restricted manipulation of TMOD2 function in specific dendritic segments or individual spines.

• FRAP and photoactivation: These techniques could reveal the dynamics of TMOD2 turnover and mobility within different neuronal compartments.

• Split fluorescent protein complementation: This approach could be used to visualize TMOD2 interactions with specific binding partners (tropomyosin, actin) in living neurons.

Research has already demonstrated that TMOD2's capping ability affects spine dynamics differently in mature versus immature spines, highlighting the importance of studying these processes in living neurons .

How might TMOD2 research contribute to understanding neurological disorders?

TMOD2 research has significant implications for understanding neurological disorders:

• Learning and memory disorders: TMOD2 knockout studies in mice have shown hyperactivity, learning/memory impairments, and increased long-term potentiation , suggesting TMOD2 dysfunction may contribute to cognitive disorders.

• Neurodevelopmental disorders: Given TMOD2's role in dendritic spine development and neuronal morphology, alterations in TMOD2 function could contribute to neurodevelopmental disorders characterized by abnormal spine density or morphology, such as autism spectrum disorders.

• Synaptic plasticity deficits: TMOD2's regulation of spine dynamics and shaft synapse formation implicates it in synaptic plasticity mechanisms that are often disrupted in various neurological conditions.

• Excitatory/inhibitory balance: The finding that disrupting TMOD2's tropomyosin-binding ability increases excitatory shaft synapses suggests it may play a role in regulating excitatory/inhibitory balance, which is disturbed in many neurological disorders.

• Cytoskeletal-based approaches: Understanding how TMOD2 regulates actin dynamics in neurons could inform the development of cytoskeletal-based therapeutic approaches for conditions involving aberrant neuronal morphology or connectivity.